About Puma Biotechnology, Inc.
https://www.pumabiotechnology.comPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
CEO
Alan H. Auerbach
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:4.13M
Value:$26.52M
VANGUARD GROUP INC
Shares:3.69M
Value:$23.7M
BLACKROCK, INC.
Shares:3.58M
Value:$22.97M
Summary
Showing Top 3 of 172
About Puma Biotechnology, Inc.
https://www.pumabiotechnology.comPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $54.48M ▲ | $32.73M ▼ | $8.84M ▲ | 16.23% ▲ | $0.18 ▲ | $13.45M ▲ |
| Q2-2025 | $52.44M ▲ | $33.5M ▲ | $5.86M ▲ | 11.17% ▲ | $0.12 ▲ | $10.77M ▲ |
| Q1-2025 | $46.01M ▼ | $31.47M ▼ | $2.97M ▼ | 6.46% ▼ | $0.06 ▼ | $8.24M ▼ |
| Q4-2024 | $59.08M ▼ | $31.79M ▲ | $19.3M ▼ | 32.68% ▲ | $0.39 ▼ | $17.7M ▼ |
| Q3-2024 | $80.54M | $29.37M | $20.32M | 25.23% | $0.41 | $26.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $94.39M ▼ | $202.86M ▲ | $87.59M ▼ | $115.27M ▲ |
| Q2-2025 | $96.02M ▲ | $194.92M ▼ | $90.2M ▼ | $104.72M ▲ |
| Q1-2025 | $93.17M ▼ | $196.18M ▼ | $99.07M ▼ | $97.11M ▲ |
| Q4-2024 | $100.97M ▲ | $213.33M ▼ | $121.21M ▼ | $92.13M ▲ |
| Q3-2024 | $96.72M | $220.72M | $149.63M | $71.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.84M ▲ | $9.69M ▼ | $506K ▲ | $-11.33M ▼ | $-1.14M ▲ | $9.66M ▼ |
| Q2-2025 | $5.86M ▲ | $14.08M ▲ | $-11.25M ▼ | $-11.2M ▲ | $-8.37M ▼ | $14.06M ▲ |
| Q1-2025 | $2.97M ▼ | $3.61M ▼ | $1.53M ▲ | $-11.33M ▼ | $-6.19M ▼ | $3.55M ▼ |
| Q4-2024 | $19.3M ▼ | $15.61M ▲ | $-2.32M ▼ | $-11.33M ▼ | $1.96M ▲ | $15.59M ▲ |
| Q3-2024 | $20.32M | $11.04M | $259K | $-11.18M | $114K | $11.02M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $90.00M ▲ | $40.00M ▼ | $50.00M ▲ | $50.00M ▲ |
 Royalty | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Alan H. Auerbach
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:4.13M
Value:$26.52M
VANGUARD GROUP INC
Shares:3.69M
Value:$23.7M
BLACKROCK, INC.
Shares:3.58M
Value:$22.97M
Summary
Showing Top 3 of 172